The global perennial allergic rhinitis market is expected to show a significant growth rate during the forecast period. Increasing demand for effective and potent drugs high prevalence of the disease, increasing respiratory disorders, and changing lifestyles such as smoking are the high impact rendering driver for the growth of the market. According to the (WAO) World Allergy Organization, the prevalence of allergic rhinitis in 2012 was 1.4% to 40% in various countries around the globe. Increasing prevalence of asthma and other respiratory disorders, growing R&D initiatives pertaining to the development of new products, and the presence of strong pipeline portfolio are influencing the market growth. Around 75% of asthma patients suffer from concomitant allergic rhinitis.
Perennial allergic rhinitis also called hay fever or pollinosis often goes unnoticed since its symptoms coincide with the symptoms of common cold. Perennial allergic rhinitis is the most common and frequently occurring type of allergic rhinitis. Major symptoms of the disease are sneezing, itching, nasal obstruction, congestion, and rhinorrhea. The presence of disease is diagnosed by using various tests such as skin test (patch test), allergen sensitivity test, radioallergosorbent testing, blood test, and skin prick test.
Perennial Allergic rhinitis market is segmented based on the products into anti-histamines, decongestants, steroids, and other treatments such as immunotherapy formulas which include desensitizing vaccines, leukotriene receptor antagonists, cromolyn formulas (sodium cromoglycate) and others. Anti-histamines include drugs such as Loratadine (Claritin), fexofenadine (Allerga), diphenhydramine (Benadryl). Decongestants include Afrin and Sudafed. steroids class mainly includes nasal corticosteroids such as Fluticasone (Nasonex) Triamcinolone (Nasacort), beclometasone (Beconase), prednisolone, triamcinolone acetonide.
Geographically the market is segmented into regions such as North America, Europe, Asia Pacific, Latin America, and MEA. Europe held the largest market share in 2013 owing to the high market penetration rates of drugs such as Xolair. Whereas, Asia Pacific is expected to show remarkable development owing to rising patients awareness, growing prevalence of the disorder, presence of high unmet needs, and growing healthcare infrastructure.
Some major players operating for the perennial allergic rhinitis market include Alcon Inc Merck & Co. Inc., Biopharma, Sumitomo Pharma co, Genentech, Inc., Pfizer, Inc., Hanmi Pharmaceuticals, Inc. Hisamitsu Pharmaceutical Co., and Teva Pharmaceutical Ltd.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."